Comparable stake leader
EVENTIDE ASSET MANAGEMENT, LLC
SEC ownership of Beta Bionics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001674632.
Disclosed value leader
Zone Healthcare Holdings, LLC
Comparable rows
50/50
Latest evidence
21 May 2026
- Symbol
- BBNX on Nasdaq
- Ownership evidence mix
- 13F, 13D/G, and 3/4/5
- Largest current holder
- EVENTIDE ASSET MANAGEMENT, LLC
- Latest large-stake holder
- EVENTIDE ASSET MANAGEMENT, LLC
- Latest evidence date
- 21 May 2026
- CIK
- 0001674632
- Location
- Irvine, CA
Ownership snapshot
2 signals
Issuer identity
2 identity fields
Ownership snapshot
Top shareholders of Beta Bionics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
EVENTIDE ASSET MANAGEMENT...
Disclosed value leader
Zone Healthcare Holdings,...
Comparable rows
50/50
Latest evidence
21 May 2026
13F
13D/G
3/4/5
Lead comparable stake: 13%
13D/G row: EVENTIDE ASSET MANAGEMENT, LLC
Showing 1-8 of 50 holder rows.
Quick read
EVENTIDE ASSET MANAGEMENT, LLC leads the comparable SEC ownership view at 13%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
EVENTIDE ASSET MANAGEMENT, LLC
13%
Zone Healthcare Holdings, LLC
9.9%
Soleus Capital Group, LLC
9.8%
MORGAN STANLEY
8.6%
Sands Capital Life Sciences Pulse...
8.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
13D/G
Company
|
13%
from 13D/G
|
$59,567,287
5,945,488 shares
|
— | 31 Mar 2026 |
| Zone Healthcare Holdings, LLC |
13D/G
Dapice Joshua J.
|
9.9%
|
$85,717,590
4,313,920 shares
|
+$17,618,729 | 30 Sep 2025 |
| Soleus Capital Group, LLC |
13D/G
Levy Guy
|
9.8%
|
$38,580,879
4,354,501 shares
|
$0 | 31 Mar 2026 |
| MORGAN STANLEY |
13D/G
13F
Company
|
8.6%
|
$74,305,196
3,739,567 shares
|
+$16,109,185 | 30 Sep 2025 |
| Sands Capital Life Sciences Pulse Fund II, L.P. |
13D/G
|
8.2%
|
$48,410,732
3,570,113 shares
|
+$5,636,946 | 30 Jun 2025 |
| Farallon Capital Partners, L.P. |
13D/G
Dapice Joshua J.
|
8.1%
|
$31,966,171
3,607,920 shares
|
-$6,839,920 | 31 Mar 2026 |
| BlackRock, Inc. |
13D/G
13F
Company
|
6.4%
|
$55,215,708
2,778,764 shares
|
$0 | 30 Sep 2025 |
| Point72 Asset Management, L.P. |
13D/G
13F
Company
|
5.2%
|
$34,190,043
2,290,023 shares
|
$0 | 18 Feb 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$3,108,843.
Buys
$0
Insiders: 0
Sells
$3,108,843
Insiders: 8
Net
-$3,108,843
Shares: -139,801
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 139,801
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 4,349 | $0 | $45,102 | -$45,102 |
| 3-6 | 0 | 32,061 | $0 | $951,044 | -$951,044 |
| 6-9 | 0 | 61,502 | $0 | $1,385,069 | -$1,385,069 |
| 9-12 | 0 | 41,889 | $0 | $727,628 | -$727,628 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-12 of 12 reporting-owner rows connected to Beta Bionics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
12
Largest current holder
Sean Saint
Net 12M change
-$2,966,468
Latest report
21 May 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Sean Saint | President & CEO, Director | $5,412,019 | -$159,525 | -2.9% | Filing P/S | 27 Feb 2026 |
| Steven Jon Russell | Chief Medical Officer | $5,223,873 | -$49,215 | -0.93% | Filing P/S | 27 Feb 2026 |
| Mark Hopman | Chief Commercial Officer | $4,176,518 | -$747,597 | -15% | Filing P/S | 04 Mar 2026 |
| Mike Mensinger | Chief Product Officer | $2,333,783 | -$348,897 | -13% | Filing P/S | 27 Feb 2026 |
| Stephen Feider | Chief Financial Officer | $2,135,206 | -$1,461,508 | -41% | Filing P/S | 27 Feb 2026 |
| Adam Lezack | Director | $591,679 | -$100,460 | -15% | Mixed | 21 May 2026 |
| Gerard J. Michel | Director | $335,760 | Median | 21 May 2026 | ||
| Danny L. Dearen | Director | $322,734 | Median | 21 May 2026 | ||
| Sean Carney | Director | $322,734 | Median | 21 May 2026 | ||
| Christy Jones | Director | $302,714 | -$19,880 | -6.2% | Median | 21 May 2026 |
| Maria Palasis | Director | $294,557 | -$79,386 | -21% | Median | 21 May 2026 |
| Wellington Hadley Harbor Aggregator IV, L.P. | 10%+ Owner | $78,032 | Filing P/S | 31 Jan 2025 |
Recent insider transactions for Beta Bionics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Adam Lezack | BBNX | Comon Stock | Sale | -3.51% | $11,188 | $11.21 | -998 | 27,399 | 22 May 2026 | Direct |
| Gerard J. Michel | BBNX | Common Stock | Award | 102.5% | 16,965 | 33,509 | 21 May 2026 | Direct | ||
| Christy Jones | BBNX | Common Stock | Award | 128.1% | 16,965 | 30,211 | 21 May 2026 | Direct | ||
| Christy Jones | BBNX | Common Stock | Sale | -13.1% | $19,880 | $9.95 | -1,998 | 13,246 | 21 May 2026 | Direct |
| Maria Palasis | BBNX | Common Stock | Award | 136.5% | 16,965 | 29,397 | 21 May 2026 | Direct | ||
| Danny L. Dearen | BBNX | Common Stock | Award | 111.3% | 16,965 | 32,209 | 21 May 2026 | Direct | ||
| Sean Carney | BBNX | Common Stock | Award | 111.3% | 16,965 | 32,209 | 21 May 2026 | Direct | ||
| Adam Lezack | BBNX | Common Stock | Award | 148.4% | 16,965 | 28,397 | 21 May 2026 | Direct | ||
| Adam Lezack | BBNX | Common Stock | Sale | -8.04% | $9,950 | $9.95 | -1,000 | 11,432 | 21 May 2026 | Direct |
| Mark Hopman | BBNX | Common Stock | Sale | -0.25% | $4,084 | $11.57 | -353 | 139,133 | 04 Mar 2026 | Direct |
| Mike Mensinger | BBNX | Employee Stock Option (right to buy) | Award | 91,520 | 91,520 | 27 Feb 2026 | Direct | |||
| Steven Jon Russell | BBNX | Employee Stock Option (right to buy) | Award | 91,520 | 91,520 | 27 Feb 2026 | Direct | |||
| Sean Saint | BBNX | Employee Stock Option (right to buy) | Award | 287,944 | 287,944 | 27 Feb 2026 | Direct | |||
| Mark Hopman | BBNX | Employee Stock Option (right to buy) | Award | 91,520 | 91,520 | 27 Feb 2026 | Direct | |||
| Stephen Feider | BBNX | Employee Stock Option (right to buy) | Award | 110,342 | 110,342 | 27 Feb 2026 | Direct | |||
| Gerard J. Michel | BBNX | Common Stock | Award | 31.9% | 3,997 | 16,544 | 13 Jan 2026 | Direct | ||
| Sean Carney | BBNX | Common Stock | Award | 35.5% | 3,997 | 15,244 | 13 Jan 2026 | Direct | ||
| Maria Palasis | BBNX | Common Stock | Award | 47.4% | 3,997 | 12,432 | 13 Jan 2026 | Direct | ||
| Christy Jones | BBNX | Common Stock | Award | 35.5% | 3,997 | 15,244 | 13 Jan 2026 | Direct | ||
| Adam Lezack | BBNX | Common Stock | Award | 47.4% | 3,997 | 12,432 | 13 Jan 2026 | Direct | ||
| Danny L. Dearen | BBNX | Common Stock | Award | 35.5% | 3,997 | 15,244 | 13 Jan 2026 | Direct | ||
| Mike Mensinger | BBNX | Common Stock | Sale | -2.65% | $66,221 | $30.10 | -2,200 | 80,752 | 06 Jan 2026 | Direct |
| Mike Mensinger | BBNX | Common Stock | Sale | -8.59% | $230,950 | $29.61 | -7,800 | 82,952 | 02 Jan 2026 | Direct |
| Stephen Feider | BBNX | Common Stock | Sale | -31.9% | $590,680 | $29.53 | -20,000 | 42,614 | 02 Jan 2026 | Direct |
| Stephen Feider | BBNX | Common Stock | Options Exercise | 46.9% | 20,000 | 62,614 | 02 Jan 2026 | Direct | ||
| Stephen Feider | BBNX | Employee Stock Option (right to buy) | Options Exercise | -28.7% | -20,000 | 49,695 | 02 Jan 2026 | Direct | ||
| Mark Hopman | BBNX | Common Stock | Sale | -1.49% | $63,192 | $30.66 | -2,061 | 136,216 | 04 Dec 2025 | Direct |
| Mark Hopman | BBNX | Common Stock | Sale | -0.62% | $25,112 | $29.34 | -856 | 138,277 | 02 Dec 2025 | Direct |
| Steven Jon Russell | BBNX | Common Stock | Sale | -0.57% | $30,069 | $29.34 | -1,025 | 178,071 | 02 Dec 2025 | Direct |
| Mike Mensinger | BBNX | Common Stock | Sale | -1.16% | $31,184 | $29.34 | -1,063 | 90,752 | 02 Dec 2025 | Direct |
| Stephen Feider | BBNX | Common Stock | Sale | -3.24% | $41,862 | $29.34 | -1,427 | 42,614 | 02 Dec 2025 | Direct |
| Sean Saint | BBNX | Common Stock | Sale | -3.24% | $96,163 | $29.34 | -3,278 | 97,924 | 02 Dec 2025 | Direct |
| Adam Lezack | BBNX | Common Stock | Sale | -14.3% | $41,543 | $29.55 | -1,406 | 8,435 | 01 Dec 2025 | Direct |
| Maria Palasis | BBNX | Common Stock | Sale | -14.3% | $41,552 | $29.55 | -1,406 | 8,435 | 01 Dec 2025 | Direct |
| Adam Lezack | BBNX | Common Stock | Sale | -12.5% | $37,780 | $26.87 | -1,406 | 9,841 | 31 Oct 2025 | Direct |
| Maria Palasis | BBNX | Common Stock | Sale | -12.5% | $37,834 | $26.91 | -1,406 | 9,841 | 31 Oct 2025 | Direct |
| Stephen Feider | BBNX | Common Stock | Sale | -10.2% | $108,076 | $21.69 | -4,982 | 44,041 | 03 Oct 2025 | Direct |
| Stephen Feider | BBNX | Common Stock | Options Exercise | 11.3% | 4,982 | 49,023 | 03 Oct 2025 | Direct | ||
| Stephen Feider | BBNX | Employee Stock Option (right to buy) | Options Exercise | -6.67% | -4,982 | 69,695 | 03 Oct 2025 | Direct | ||
| Stephen Feider | BBNX | Common Stock | Sale | -25.4% | $311,806 | $20.76 | -15,018 | 44,041 | 01 Oct 2025 | Direct |
| Stephen Feider | BBNX | Common Stock | Options Exercise | 34.1% | 15,018 | 59,059 | 01 Oct 2025 | Direct | ||
| Stephen Feider | BBNX | Employee Stock Option (right to buy) | Options Exercise | -16.7% | -15,018 | 74,677 | 01 Oct 2025 | Direct | ||
| Stephen Feider | BBNX | Common Stock | Sale | -18.4% | $209,151 | $21.13 | -9,900 | 44,041 | 08 Sep 2025 | Direct |
| Stephen Feider | BBNX | Common Stock | Options Exercise | 22.5% | 9,900 | 53,941 | 08 Sep 2025 | Direct | ||
| Stephen Feider | BBNX | Employee Stock Option (right to buy) | Options Exercise | -9.94% | -9,900 | 89,695 | 08 Sep 2025 | Direct | ||
| Mark Hopman | BBNX | Common Stock | Sale | -26.8% | $234,657 | $20.56 | -11,411 | 31,215 | 05 Sep 2025 | Direct |
| Mark Hopman | BBNX | Common Stock | Options Exercise | 36.6% | 11,411 | 42,626 | 05 Sep 2025 | Direct | ||
| Mark Hopman | BBNX | Employee Stock Option (right to buy) | Options Exercise | -34.4% | -11,411 | 21,725 | 05 Sep 2025 | Direct | ||
| Stephen Feider | BBNX | Common Stock | Sale | -0.23% | $2,100 | $21.00 | -100 | 44,041 | 05 Sep 2025 | Direct |
| Stephen Feider | BBNX | Common Stock | Options Exercise | 0.23% | 100 | 44,141 | 05 Sep 2025 | Direct |
* marks a reported price that did not pass the local price check.